Gastrointestinal Cancer Program

胃肠道癌症计划

• 批准号: 10362650
• 负责人: Tanios Bekaii-Saab
• 金额: $ 9.96万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-25 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10362650
• 关键词: Achievement; Address; Area; Award; Basic Science; Cancer Center Support Grant; Catchment Area; Cessation of life; Clinic; Clinical Research; Clinical Trials; Collaborations; Comprehensive Cancer Center; Development; Diagnosis; Disease; Early Diagnosis; Evaluation; Faculty; Funding; Germ-Free; Goals; Grant; Healthcare; Hepatobiliary; Incidence; Infrastructure; Investigation; Journals; Knowledge; Literature; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of liver; Malignant neoplasm of pancreas; Mayo Clinic Cancer Center; Mentors; Mentorship; Mission; Mus; Outcome; Outcomes Research; Pathogenesis; Patient Care; Patient-Focused Outcomes; Patients; Peer Review; Prevention; Prognostic Marker; Publications; Research; Research Personnel; Resource Sharing; Resources; Risk; Role; Science; Scientific Advances and Accomplishments; Site; Stratification; Talents; Testing; Translational Research; United States National Institutes of Health; Work; anticancer research; base; cancer diagnosis; care outcomes; design; effective therapy; gut microbiome; improved; individualized medicine; innovation; insight; member; metabolomics; microbiome; multidisciplinary; new therapeutic target; novel; novel marker; novel strategies; predictive marker; programs; therapy outcome; tumor microbiome; tumor microenvironment

GASTROINTESTINAL CANCER PROGRAM PROJECT SUMMARY The Gastrointestinal Cancer (GI) Program of the Mayo Clinic Cancer Center (MCCC) continues to make significant contributions in the areas of basic, translational, and clinical research by using a multidisciplinary and interactive team approach. The primary objective of the GI Program is to use novel observations, mechanistic insights and research outcomes to benefit patients with GI cancers or at risk for GI malignancies, including those from our catchment area. This work is accomplished through robust intra- and interprogrammatic interactions focused on 4 Aims: 1) application of early detection approaches, 2) identification and evaluation of predictive or prognostic biomarkers, 3) role of the tumor microenvironment and microbiome in cancer development and progression, and 4) individualized therapeutic strategies. Aim 3 is a new and evolving effort that builds upon an existing base of NCI-funded investigators in these fields of research, and interacts with the Microbiome Program within the Mayo Clinic Center for Individualized Medicine to expand the existing germ-free mouse facility and a metabolomics core lab. The GI Program consists of 54 members from 17 departments. Our GI Program developed a SPORE grant in Pancreatic Cancer where major contributions and interactions continue. The GI Program also developed a Hepatobiliary (HB) SPORE proposal that received a highly competitive score with a funding decision expected in mid-2018. As a result of this score, the MCCC was awarded a CCSG supplement of $750K from the NCI with an aim to maintain the infrastructure for liver cancer research. Our NIH-funded research platform and portfolio of innovative clinical trials is expanding and benefits from interactions across the 3 MCCC sites and with other multi-institutional networks; these interactions are enhancing accrual. The GI research program is supported by total direct funding of $10.2M ($5.1M peer-reviewed, with 69% from NCI). Since 2013, Program members have contributed more than 871 publications to the literature, of which 28% represent intraprogrammatic and 31% reflect interprogrammatic collaborations; 21% are in journals with an impact factor ≥10. These publications reflect numerous scientific accomplishments and discoveries, several of which have been practice changing. Formal mentoring of junior faculty continues with an increased effort to provide pilot grant funding to our investigators.

胃肠道癌症计划摘要 梅奥诊所癌症中心（MCCC）的胃肠癌（GI）计划继续使 通过使用多学科的基础，翻译和临床研究领域的重要贡献 和互动团队的方法。 GI计划的主要目的是使用新颖的观察结果， 机械洞察和研究结果，使GI癌患者受益或有GI MALIGNANCYS风险， 包括我们集水区的那些。这项工作是通过强大的内部和 重点是4个目的：1）早期检测方法的应用，2） 鉴定和评估预测性或预后生物标志物，3）肿瘤微环境和 癌症发展和进展的微生物组，以及4）个性化的治疗策略。目标3是 在这些领域的NCI资助的研究人员的现有基础上建立了新的和不断发展的努力 研究，并与梅奥诊所个性化医学中心的微生物组计划互动 扩展现有的无菌小鼠设施和代谢组学核心实验室。 GI计划包括54 来自17个部门的成员。我们的GI计划在胰腺癌中开发了一份孢子补助金 贡献和互动仍在继续。 GI计划还开发了肝素（HB）孢子提案 这获得了竞争激烈的得分，预计将于2018年中期做出资金决定。由于这个分数， MCCC获得了NCI $ 750K的CCSG补品，目的是维护基础设施 用于肝癌研究。我们由NIH资助的研究平台和创新临床试验的投资组合是 在3个MCCC站点以及其他多机构网络之间的互动中扩展和受益； 这些相互作用正在增强质量。 GI研究计划得到了全面直接资助的支持 1,020万美元（经过510万美元的同行评审，NCI的69％）。自2013年以来，计划成员贡献了更多 比文献的871个出版物，其中28％代表截面图，31％反映 分解合作协作； 21％的人为影响因子≥10。这些出版物反映了 许多科学成就和发现，其中一些正在练习改变。正式的 对初级教师的指导继续努力为我们的调查人员提供试点赠款资金。